

# Yizhen Pang

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1297908/publications.pdf>

Version: 2024-02-01

23  
papers

1,259  
citations

687220

13  
h-index

677027

22  
g-index

23  
all docs

23  
docs citations

23  
times ranked

487  
citing authors

#	ARTICLE	IF	CITATIONS
1	Comparison of [68Ga]Ga-DOTA-FAPI-04 and [18F] FDG PET/CT for the diagnosis of primary and metastatic lesions in patients with various types of cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 1820-1832.	3.3	348
2	Comparison of <sup>68</sup> Ga-FAPI and <sup>18</sup> F-FDG Uptake in Gastric, Duodenal, and Colorectal Cancers. <i>Radiology</i> , 2021, 298, 393-402.	3.6	171
3	Usefulness of [68Ga]Ga-DOTA-FAPI-04 PET/CT in patients presenting with inconclusive [18F]FDG PET/CT findings. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 73-86.	3.3	153
4	Imaging fibroblast activation protein in liver cancer: a single-center post hoc retrospective analysis to compare [68Ga]Ga-FAPI-04 PET/CT versus MRI and [18F]-FDG PET/CT. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 1604-1617.	3.3	100
5	Role of [68Ga]Ga-DOTA-FAPI-04 PET/CT in the evaluation of peritoneal carcinomatosis and comparison with [18F]-FDG PET/CT. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 1944-1955.	3.3	75
6	Fibroblast activation protein-based theranostics in cancer research: A state-of-the-art review. <i>Theranostics</i> , 2022, 12, 1557-1569.	4.6	61
7	Synthesis, Preclinical Evaluation, and a Pilot Clinical PET Imaging Study of <sup>68</sup> Ga-Labeled FAPI Dimer. <i>Journal of Nuclear Medicine</i> , 2022, 63, 862-868.	2.8	59
8	Clinical utility of [68Ga]Ga-labeled fibroblast activation protein inhibitor (FAPI) positron emission tomography/computed tomography for primary staging and recurrence detection in nasopharyngeal carcinoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 3606-3617.	3.3	50
9	Positron emission tomography and computed tomography with [68Ga]Ga-fibroblast activation protein inhibitors improves tumor detection and staging in patients with pancreatic cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 1322-1337.	3.3	49
10	[18F]FDG and [68Ga]Ga-DOTA-FAPI-04 PET/CT in the evaluation of tuberculous lesions. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 651-652.	3.3	42
11	<sup>68</sup> Ga-fibroblast activation protein inhibitor PET/CT on gross tumour volume delineation for radiotherapy planning of oesophageal cancer. <i>Radiotherapy and Oncology</i> , 2021, 158, 55-61.	0.3	36
12	Comparison of <sup>68</sup> Ga-FAPI and <sup>18</sup> F-FDG PET/CT in a Patient With Cholangiocellular Carcinoma. <i>Clinical Nuclear Medicine</i> , 2020, 45, 566-567.	0.7	29
13	<sup>68</sup> Ga-FAPI PET/CT Versus <sup>18</sup> F-FDG PET/CT for Detecting Metastatic Lesions in a Case of Radioiodine-Refractory Differentiated Thyroid Cancer. <i>Clinical Nuclear Medicine</i> , 2021, 46, 940-942.	0.7	18
14	FAP-targeted radionuclide therapy with [177Lu]Lu-FAPI-46 in metastatic nasopharyngeal carcinoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 1767-1769.	3.3	16
15	<sup>68</sup> Ga-Fibroblast Activation Protein Inhibitor, a Promising Radiopharmaceutical in PET/CT to Detect the Primary and Metastatic Lesions of Chromophobe Renal Cell Carcinoma. <i>Clinical Nuclear Medicine</i> , 2021, 46, 177-179.	0.7	13
16	<sup>68</sup> Ga-FAPI PET/CT Distinguishes the Reactive Lymph Nodes From Tumor Metastatic Lymph Nodes in a Patient With Nasopharyngeal Carcinoma. <i>Clinical Nuclear Medicine</i> , 2022, 47, 367-368.	0.7	10
17	<sup>68</sup> Ga-FAPI PET/CT detected non-FDG-avid bone metastases in breast cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 2096-2097.	3.3	8
18	Somatostatin receptor imaging with [68Ga]Ga-DOTATATE positron emission tomography/computed tomography (PET/CT) in patients with nasopharyngeal carcinoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 1360-1373.	3.3	7

#	ARTICLE	IF	CITATIONS
19	Cardiac angiosarcoma detected using <sup>68</sup> Ga-fibroblast activation protein inhibitor positron emission tomography/magnetic resonance. <i>European Heart Journal</i> , 2021, 42, 1276-1276.	1.0	6
20	<sup>18</sup> F-FDG Versus <sup>68</sup> Ga-FAPI PET/CT in Visualizing Primary Hepatic Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue. <i>Clinical Nuclear Medicine</i> , 2022, 47, 375-377.	0.7	4
21	Increased [ <sup>68</sup> Ga]Ga-FAPI uptake in focal nodular hyperplasia in a patient with sigmoid colon cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 49, 415-416.	3.3	2
22	[ <sup>68</sup> Ga]Ga-FAPI PET/CT imaging of brown tumors in a patient with primary hyperparathyroidism. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 1770-1771.	3.3	1
23	Dual Targeting of Integrin $\alpha_5\beta_1$ and Neuropilin-1 Receptors Improves Micropositron Emission Tomography Imaging of Breast Cancer. <i>Molecular Pharmaceutics</i> , 2022, 19, 1458-1467.	2.3	1